gsk glp-1 Agonists - What is it? Glucagon-like peptide 1 (GLP-1) -

Yes, laxatives can generally be used safely alongside GLP-1 medications like Ozempic, semaglutide, and tirzepatidebut timing, type, and dose matter significantly

Serious Urinary Tract Infections Inform patients of the potential for urinary tract infections, which may be serious

These medications mimic the actions of the endogenous incretin hormone GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety.[1] Incretin hormones also exert effects across multiple organ systems, including cardiovascular, renal, and skeletal systems.[1] Owing to these pleiotropic mechanisms, the clinical use of GLP-1RAs has expanded exponentially, both for diabetes and for a broadening spectrum of diseases and conditions.[2] Obesity plays a central role in the pathogenesis and progression of T2DM, yet many traditional glucose-lowering therapies are associated with weight gain.[3] The observation that GLP-1RAs not only improve glycemic control but also result in significant weight loss marked a paradigm shift in diabetes pharmacotherapy, prompting investigation into their therapeutic potential in individuals without diabetes to treat obesity and related comorbidities.[4] Subsequently, large-scale cardiovascular and kidney outcome trials have demonstrated additional benefits of GLP-1RAs, further supporting their use in high-risk populations independent of diabetes status.[4] These trials resulted in a rapid evolution of the clinical landscape for GLP-1RAs in the last decade, with growing evidence supporting their role in treating obesity, cardiovascular disease, chronic kidney disease (CKD), and other metabolic-related disorders.[520] This expansion reflects both their favorable efficacy profile and their broader physiological effects

Fuemmeler, PhD, MPH, professor of family medicine and associate director of population science at VCUs Massey Comprehensive Cancer Center sought to clarify the effects of GLP-1s on outcomes among women with breast cancer

Studies have found GLP-1RA discontinuation rates of 36%81% in the first year of treatment